ARTICLE | Clinical News
CUDC-907: Additional Phase I data
June 15, 2015 7:00 AM UTC
Data from 10 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation, U.S. Phase I trial showed that CUDC-907 led to 2 complete responses...